Overview
Belgium particle accelerator tech firm's FY 2025 sales rose 24%, beating analyst expectations
Adjusted EBIT for FY 2025 increased 58% yr/yr, driven by strong Proton Therapy contribution
Company launched share buyback program post period end for up to 400,000 shares
Outlook
IBA sets FY 2026 group adjusted EBIT guidance of at least €32 mln
Company reaffirms its mid-term outlook
Company expects working capital improvement to accelerate from 2027
Result Drivers
PROTON THERAPY GROWTH - Strong execution and commercial momentum in Proton Therapy drove 44% net sales growth and a significant positive contribution to Adjusted EBIT
ORDER INTAKE & BACKLOG - Record equipment order intake and all-time high backlog provided significant revenue visibility
EQUIPMENT PROFITABILITY MIX - Gross margin declined to 32.2% due to less favorable equipment profitability mix, including legacy low-margin Proton Therapy projects, partially offset by productivity improvements
Company press release: ID:nGNE2CZN1H
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Beat
EUR 620.20 mln
EUR 597.08 mln (4 Analysts)
FY Net Income
EUR 12.70 mln
FY Gross Margin
32.20%
FY Pretax Profit
EUR 18.80 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)